China Universal Asset Management Co., Ltd. Provention Bio, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$700 Million
Q2 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 21, 2024	BUY	$6.7 - $24.21 $1,976 - $7,141	295 Added 33.3%	1,181 $28,000
Q1 2023 Apr 27, 2023	BUY	$6.7 - $24.21 $1,976 - $7,141	295 Added 33.3%	1,181 $28,000
Q4 2022 May 21, 2024	BUY	$4.52 - $10.57 $4,004 - $9,365	886 New	886 $9,000
Q4 2022 Jan 31, 2023	BUY	$4.52 - $10.57 $551 - $1,289	122 Added 15.97%	886 $9,000
Q3 2022 Oct 21, 2022	BUY	$3.43 - $5.62 $2,620 - $4,293	764 New	764 $3,000

Others Institutions Holding PRVB

# of Institutions

Shares Held

170K

Call Options Held

Put Options Held

Odey Asset Management Group LTD London, X0

170K
Shares

$0
1.36% of portfolio

View Full List

About Provention Bio, Inc.

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

More about PRVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account